Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

This study tests a combination of low-dose venetoclax (a cancer cell death drug), itraconazole (a drug that increases venetoclax levels in the blood), and a chemotherapy regimen called TACL in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) — a blood cancer that has returned or stopped responding to treatment. **You may be eligible if...** - You have B-cell or T-cell acute lymphoblastic leukemia (ALL) - Your cancer does not have the Philadelphia chromosome abnormality - Your cancer has relapsed (come back) after remission or is refractory (not responding) to first-line treatment - You have not previously received venetoclax **You may NOT be eligible if...** - You have the Philadelphia chromosome-positive form of ALL - You have received venetoclax as part of prior treatment - You have uncontrolled infections or very poor organ function Talk to your doctor to see if this trial is right for you.